Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells

OBJECTIVES: Immunotherapy that targets the programmed death-1 / programmed death-ligand 1 (PD-L1) axis has been approved for treatment of non-small cell lung cancer (NSCLC) patients in many countries. However, our current understanding of the role of immunotherapies on NSCLC patients with epidermal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer
Main Authors: Suda, Kenichi, Rozeboom, Leslie, Rivard, Christopher J., Yu, Hui, Ellison, Kim, Melnick, Mary Ann C., Hinz, Trista K., Chan, Daniel, Heasley, Lynn E., Politi, Katerina, Mitsudomi, Tetsuya, Hirsch, Fred R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174882/
https://ncbi.nlm.nih.gov/pubmed/28577937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2017.04.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados